Metastatic Castration Resistant Prostate Cancer clinical trials

Explore recruiting metastatic castration resistant prostate cancer clinical trials.

Recruiting metastatic castration resistant prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castration Resistant Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Belgium, Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer

France, Belgium, Spain, Poland, Italy, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

France, Finland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Metastatic Castration Resistant Prostate Cancer trials by city

Metastatic Castration Resistant Prostate Cancer in Toronto Metastatic Castration Resistant Prostate Cancer in Vancouver Metastatic Castration Resistant Prostate Cancer in Montreal Metastatic Castration Resistant Prostate Cancer in Calgary Metastatic Castration Resistant Prostate Cancer in Edmonton Metastatic Castration Resistant Prostate Cancer in Ottawa Metastatic Castration Resistant Prostate Cancer in Winnipeg Metastatic Castration Resistant Prostate Cancer in Quebec City Metastatic Castration Resistant Prostate Cancer in Hamilton Metastatic Castration Resistant Prostate Cancer in Kitchener Metastatic Castration Resistant Prostate Cancer in London Metastatic Castration Resistant Prostate Cancer in Halifax Metastatic Castration Resistant Prostate Cancer in New York Metastatic Castration Resistant Prostate Cancer in Los Angeles Metastatic Castration Resistant Prostate Cancer in Chicago Metastatic Castration Resistant Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease